Technical Analysis for CMRX - Chimerix, Inc.

Grade Last Price % Change Price Change
D 7.77 -5.01% -0.41
CMRX closed down 5.01 percent on Monday, April 19, 2021, on 47 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: May 5
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical CMRX trend table...

Date Alert Name Type % Chg
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Oversold Stochastic Weakness -5.01%
Oversold Stochastic Weakness -6.50%
Slingshot Bearish Bearish Swing Setup -7.17%
Stochastic Buy Signal Bullish -7.17%
Oversold Stochastic Weakness -7.17%
Oversold Stochastic Weakness -6.50%
Down 3 Days in a Row Weakness -4.90%
Down 4 Days in a Row Weakness -4.90%
Older End-of-Day Signals for CMRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% about 8 hours ago
Lower Bollinger Band Support about 8 hours ago
60 Minute Opening Range Breakdown about 9 hours ago
Down 3% about 9 hours ago
Fell Below Previous Day's Low about 10 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Chimerix, Inc. Description

Chimerix, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of oral antiviral therapeutics for various medical needs. Its lead product includes CMX001, an orally administered drug that has completed Phase II clinical trials for the prevention of cytomegalovirus infection in hematopoietic stem cell transplant recipients; and is in Phase II clinical trials for treating double-stranded DNA viruses comprising herpesviruses, adenoviruses, BK viruses, papillomaviruses, and orthopoxviruses, as well as for the treatment of smallpox. The company also develops CMX157, an oral nucleotide compound that is in Phase I clinical trials to treat HIV infections. It has a collaboration and license agreement with Merck, Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Viruses Novi Hematopoietic Stem Cell Herpes Antiviral Drug Virus Papillomavirus Ebola Prodrugs Cytomegalovirus Infection Orthopoxvirus Poxviruses

Is CMRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.5696
52 Week Low 1.37
Average Volume 716,724
200-Day Moving Average 5.41
50-Day Moving Average 9.55
20-Day Moving Average 8.75
10-Day Moving Average 8.41
Average True Range 0.58
ADX 22.13
+DI 16.15
-DI 29.50
Chandelier Exit (Long, 3 ATRs ) 8.64
Chandelier Exit (Short, 3 ATRs ) 9.50
Upper Bollinger Band 9.83
Lower Bollinger Band 7.68
Percent B (%b) 0.04
BandWidth 24.59
MACD Line -0.38
MACD Signal Line -0.28
MACD Histogram -0.0975
Fundamentals Value
Market Cap 486.67 Million
Num Shares 62.6 Million
EPS -1.32
Price-to-Earnings (P/E) Ratio -5.88
Price-to-Sales 19.93
Price-to-Book 2.67
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.46
Resistance 3 (R3) 8.53 8.37 8.35
Resistance 2 (R2) 8.37 8.19 8.34 8.31
Resistance 1 (R1) 8.07 8.09 7.99 8.00 8.27
Pivot Point 7.91 7.91 7.87 7.88 7.91
Support 1 (S1) 7.61 7.73 7.53 7.54 7.27
Support 2 (S2) 7.45 7.63 7.42 7.23
Support 3 (S3) 7.15 7.45 7.20
Support 4 (S4) 7.08